Sebastian Vandishot's questions to Valneva SE (VALN) leadership • Q2 2025
Question
An analyst on behalf of Susan from Van Lanschot Kempen asked for details on the Lyme vaccine data readout, specifically whether it would be top-line or detailed, and how the vaccine's immunogenicity compares to past Lyme vaccines.
Answer
CEO Thomas Lingelbach explained that data reporting is Pfizer's responsibility and is expected in two stages: a top-line data release first, followed by more detailed results. He noted that direct immunogenicity comparisons to older vaccines are scientifically difficult due to different trial designs, assays, and formulations, but Valneva's candidate showed favorable results in pre-clinical animal models.